
Author Index Volumes 1–4

The volume numbers are printed in italics

- Almqvist F, see Pemberton N (2006) *1*: 1–30
- Appukkuttan P, see Kaval N (2006) *1*: 267–304
- Arya DP (2006) Diazo and Diazonium DNA Cleavage Agents: Studies on Model Systems and Natural Product Mechanisms of Action. *2*: 129–152
- Bagley MC, Lubinu MC (2006) Microwave-Assisted Multicomponent Reactions for the Synthesis of Heterocycles. *1*: 31–58
- Bahal R, see Khanna S (2006) *3*: 149–182
- Basak SC, Mills D, Gute BD, Natarajan R (2006) Predicting Pharmacological and Toxicological Activity of Heterocyclic Compounds Using QSAR and Molecular Modeling. *3*: 39–80
- Benfenati E, see Duchowicz PR (2006) *3*: 1–38
- Besson T, Thiéry V (2006) Microwave-Assisted Synthesis of Sulfur and Nitrogen-Containing Heterocycles. *1*: 59–78
- Bharatam PV, see Khanna S (2006) *3*: 149–182
- Bhatarai B, see Garg R (2006) *3*: 183–273
- Brown T, Holt H Jr, Lee M (2006) Synthesis of Biologically Active Heterocyclic Stilbene and Chalcone Analogs of Combretastatin. *2*: 1–51
- Castro EA, see Duchowicz PR (2006) *3*: 1–38
- Chorell E, see Pemberton N (2006) *1*: 1–30
- Crosgnani S, Linclau B (2006) Synthesis of Heterocycles Using Polymer-Supported Reagents under Microwave Irradiation. *1*: 129–154
- Daneshtalab M (2006) Novel Synthetic Antibacterial Agents. *2*: 153–206
- Duchowicz PR, Castro EA, Toropov AA, Benfenati E (2006) Applications of Flexible Molecular Descriptors in the QSPR–QSAR Study of Heterocyclic Drugs. *3*: 1–38
- Erdélyi M (2006) Solid-Phase Methods for the Microwave-Assisted Synthesis of Heterocycles. *1*: 79–128
- Van der Eycken E, see Kaval N (2006) *1*: 267–304
- Garg R, Bhatarai B (2006) QSAR and Molecular Modeling Studies of HIV Protease Inhibitors. *3*: 183–273
- Gromiha MM, see Ponnuswamy MN (2006) *3*: 81–147
- Gupta MK, see Prabhakar YS (2006) *4*: 161–248
- Gupta SP (2006) QSAR Studies on Calcium Channel Blockers. *4*: 249–287
- Gupton JT (2006) Pyrrole Natural Products with Antitumor Properties. *2*: 53–92
- Gute BD, see Basak SC (2006) *3*: 39–80

- Hadjipavlou-Litina D (2006) QSAR and Molecular Modeling Studies of Factor Xa and Thrombin Inhibitors. *4*: 1–53
- Hannongbua S (2006) Structural Information and Drug–Enzyme Interaction of the Non-Nucleoside Reverse Transcriptase Inhibitors Based on Computational Chemistry Approaches. *4*: 55–84
- Holt H Jr, see Brown T (2006) *2*: 1–51
- Kamalesh Babu RP, see Maiti SN (2006) *2*: 207–246
- Katti SB, see Prabhakar YS (2006) *4*: 161–248
- Kaval N, Appukkuttan P, Van der Eycken E (2006) The Chemistry of 2-(1*H*)-Pyrazinones in Solution and on Solid Support. *1*: 267–304
- Khanna S, Bahal R, Bharatam PV (2006) *In silico* Studies on PPAR γ Agonistic Heterocyclic Systems. *3*: 149–182
- Lee M, see Brown T (2006) *2*: 1–51
- Linclau B, see Crosignani S (2006) *1*: 129–154
- Love BE (2006) Synthesis of Carbolines Possessing Antitumor Activity. *2*: 93–128
- Lubinu MC, see Bagley MC (2006) *1*: 31–58
- Maes BUW (2006) Transition-Metal-Based Carbon–Carbon and Carbon–Heteroatom Bond Formation for the Synthesis and Decoration of Heterocycles. *1*: 155–211
- Maiti SN, Kamalesh Babu RP, Shan R (2006) Overcoming Bacterial Resistance: Role of β -Lactamase Inhibitors. *2*: 207–246
- Mills D, see Basak SC (2006) *3*: 39–80
- Natarajan R, see Basak SC (2006) *3*: 39–80
- Pemberton N, Chorell E, Almqvist F (2006) Microwave-Assisted Synthesis and Functionalization of 2-Pyridones, 2-Quinolones and Other Ring-Fused 2-Pyridones. *1*: 1–30
- Ponnuswamy MN, Gromiha MM, Sony SMM, Saraboji K (2006) Conformational Aspects and Interaction Studies of Heterocyclic Drugs. *3*: 81–147
- Prabhakar YS, Solomon VR, Gupta MK, Katti SB (2006) QSAR Studies on Thiazolidines: A Biologically Privileged Scaffold. *4*: 161–248
- Rodriquez M, Taddei M (2006) Synthesis of Heterocycles via Microwave-Assisted Cycloadditions and Cyclocondensations. *1*: 213–266
- Saraboji K, see Ponnuswamy MN (2006) *3*: 81–147
- Shan R, see Maiti SN (2006) *2*: 207–246
- Solomon VR, see Prabhakar YS (2006) *4*: 161–248
- Sony SMM, see Ponnuswamy MN (2006) *3*: 81–147
- Taddei M, see Rodriquez M (2006) *1*: 213–266
- Thiéry V, see Besson T (2006) *1*: 59–78
- Toropov AA, see Duchowicz PR (2006) *3*: 1–38
- Vračko M (2006) QSAR Approach in Study of Mutagenicity of Aromatic and Heteroaromatic Amines. *4*: 85–106
- Zhan C-G (2006) Modeling Reaction Mechanism of Cocaine Hydrolysis and Rational Drug Design for Therapeutic Treatment of Cocaine Abuse. *4*: 107–159

Subject Index

- Acetylcholinesterase I 115; II 111, 126
Activated partial thromboplastin time (aPTT) II 7
Adenosine receptor antagonists II 187
ADME I 190
AI3-37220 I 73
AIDS I 183
AIDS-associated retrovirus I 186
Aldose reductase inhibitors II 210
3-Amidino-phenylalanine II 25
Amines II 85
-, aromatic/heteroaromatic II 99
-, mutagenicity I 56
Amino acids I 9, 17
Amino isoquinolines II 29
Aminodiols I 240
Aminoiminomethyl piperidines II 41
Aminophenol II 19
Anti-cocaine catalytic antibodies II 112, 125
Anti-diabetic agents I 149
Antiepileptic agents II 199
Antifungal agents II 224
Anti-HIV agents II 214
Anti-HIV-1 activity I 2
- potencies, HFG/GAO I 26
Anti-infective agents II 214
Anti-inflammatory agents II 177
Antistatin II 6
Antithrombotic drugs II 1
Aqueous solubility I 2
Arbitrary molecular similarity I 40
Argatroban II 35
N2-Aroylanthranilamides II 12
Artificial neural network (ANN) II 63
Aryl hydrocarbon receptor I 54
Arylquinolines I 115
ATPase inhibitors II 197
Azepines I 102
B3LYP II 113
Benzazepinone II 263
Benzodiazepines I 102
Benzopyrrolidinone derivatives II 29
Benzothiazepines I 103; II 249
Benzoxazinones II 1, 28, 75
Benzoylamine benzoic acid (BABA) I 166
Benzoylecgonine II 110
1-Benzyl-3-(5-hydroxymethyl-2-furyl) indazole II 46
Biculine I 114
Bisbenzamidine isoxazoline II 20
Blood clots II 1
Butyrylcholinesterase II 108, 111
Calcium channel blockers II 249
Carboxypiperidine I 97
Carcinogenic potential I 2
Catalytic antibody, anti-cocaine II 108, 112, 125
Catalytic triad II 3
Charge relay system II 3
Chloramphenicol-3-palmitate I 85
Chymotrypsin II 5
Clebopride I 86
Coagulation cascade II 4
Cocaine II 108
Cocaine benzoyl ester II 119
Cocaine metabolism II 110
Combinatorial design I 42
Comparative molecular field analysis (CoMFA) I 158, 192; II 8, 34, 63, 92
Comparative molecular similarity index analysis (CoMSIA) I 192; II 9, 63
Computer aided drug design (CADD) I 192
Conformation I 81
Connectivity indices I 11

- COX-2 I 62, 132
-, inhibition, imidazoles I 62
Cryptaustoline/cryptowoline I 115
Crystal structures I 81
Cyclic 3,5-nucleoside phosphates I 84
Cycloheptane I 104
Cyclohexanones I 91
Cyclooxygenase inhibitors II 177
Cyclooxygenase-2 (COX-2) I 62, 132
- DEET I 73
Deoxynojirimycin I 97
Descriptors II 85, 88
Diabetes mellitus, type 2 I 149
Diarylheterocyclic inhibitors I 132
Diarylimidazoles I 62
Diaryloxyppyridines II 18
2,6-Diarylpiperidines I 93
Diastereoisomerism, polychiral I 71
Diazepines I 102
Dibenzofuran I 54
-, receptor binding affinity I 54
Dibenzopyrrocoline alkaloids I 115
Dihydrofolate reductase inhibition I 21
Dihydropyranones I 195
1,4-Dihydropyridines II 249, 253
Dihydropyrimidines II 249
Diltiazem II 249, 251
Diniconazole I 47, 72
Diols I 240
DMP 450 I 256
DNA-dependent DNA polymerase II 58
DNA-RNA bases I 18
Drug-enzyme interaction II 56
Drug-receptor interactions, forces I 85
DX-9065a II 7
Dynamicin A I 114
- Ecgonine methyl ester II 110
Efavirenz II 58
Eicosapentaenoic acid I 167
Eicosonoids I 149
Epidermal growth factor II 4
Erectile dysfunction I 136
Estrogen receptor I 66
Extrinsic tenase II 4
- Factor Xa II 1
- inhibitors I 97
Farglitazar I 165
- Fluorobenzaldehyde I 155
- GABA agonist I 114
Gating machinery II 250
Genetic function approximation regression (GFAR) I 252
Glitazones I 71, 154
Graph of atomic orbitals (GAO) I 21
Guanine nucleotide binding proteins II 250
Guanosine monophosphate I 136, 137
- Hammett's constant II 1
Heparins (LMWHs) II 6
HEPT II 58
- derivatives I 27
Heterocycles II 1
Heterodiazepine I 102
Hierarchical molecular overlay I 71
Hierarchical quantitative structure-activity relationship (HiQSAR) I 40, 45
Histamine (H₁) antagonists II 193
HIV I 26, 185
HIV protease (HIVPR) I 186
- - inhibitors (HIVPI) I 182, 188
HIV-1 II 58
-, drug-resistant mutant II 59
HIV-1 RT, NNRTIs II 61
Hologram QSAR II 63
HTLV-III I 185
Human aldose reductase I 115
Hydrogen-filled graph I 20
Hydrolysis mechanism II 108
Hymenialdisine I 108
Hyperglycemia I 168
Hypertriglyceridemia I 168
- Ibuprofen I 84
Imidazole-4-acetic acid I 113
Imidazoles I 62, 113
Indole/benzoimidazole-5-carboxamides II 14, 35
Indoles I 114
Indoloquinoline I 115
Inositol phosphates I 84
Insulin resistance I 149, 151
Insulin sensitizers I 151
Intrinsic tenase II 4
Isoxazoles I 113
Isoxazoline derivatives II 20

- K-201 I 108
Kohonen map II 93
- Lactoyl choline I 84
LCCI I 11
LCXCT I 11
Lee–Yang–Parr correlation functional (B3LYP) II 113
LINGO I 31
Local graph invariants I 20
Lopinavir I 256
- Metabolic disorders II 201
Methyl acetate, model of cocaine methyl ester II 118
Methylchroman-2-carboxylic acids I 156
MM2 I 74
Molar absorption coefficient, DNA-RNA bases I 18
Molecular connectivity theory (MCT) I 11
Molecular descriptors I 44
Molecular docking I 149, 166
Molecular similarity, analog selection I 69
–, –, tailored approach I 67
Molecular similarity spaces I 66
Molecular simulations II 56
Morphine I 84
Mosquito repellents, overlay I 72
Mutagenicity I 2; II 85
–, amines I 56
–, GAO models I 31
Mutant protease I 256
- α -tosyl-L-arginine methyl ester (TAME) II 37
Na-tosylated 3-amidinophenylalanyl piperidide (3-TAPA) II 46
Naphthalenosulphonamide II 30
Neural network II 85
Neuropeptide Y5 receptor antagonists II 203
Nevirapine II 58
Nifedipine II 249
Nitric oxide I 137
Nitric oxide synthase inhibitors II 183
Nitrosamines I 90
Non-nucleoside reverse transcriptase inhibitor (NNRTIs) II 56
Non-peptidic inhibitors (NPPIs) I 190
Norcocaine II 110
- NSAID I 131
Nuclear hormone receptors I 162
Nuclear receptor I 149
- Octopamine agonists (OA) II 235
OCWLG I 20
ONIOM II 56
Ordinary least squares (OLS) regression I 52
Oscillator strength, DNA-RNA bases I 18
Oxadiazolidinedione I 159
Oxaminiquine I 114
Oxazolidinediones I 149, 159
2-Oxo quinoline derivatives I 114
- Partial least squares (PLS) I 52
Partial least squares regression (PLSR) I 40, 252
PDE-5 I 131, 137
Peptide-derived peptidomimetic inhibitors I 189
Peptidic protease inhibitors (PPIs) I 226
Peripheral blood mononuclear cells (PBMC) I 185
Peroxisome proliferator activated receptor γ I 149, 151; II 206
Pharmacoinformatics I 157
Pharmacophore mapping I 149
Phenoxazines I 149
Phenylalanine–phenylalanine interactions I 82
Phenylalkylamines II 249
Phenylsulfonylindolizines II 249
Phosphodiesterase I 131, 137
Phthalideisoquinoline alkaloids I 114
Picaridin I 73
Pioglitazone I 71, 149
Piperazinosulphonamide I 137
Piperidine I 73, 81, 86
–, N-nitroso compounds I 87
Piperidine-3,4-diol I 97
4-Piperidones I 87
Polymorphism I 81
PPAR agonists I 149, 156; II 206
Principal component analysis (PCA) I 45, 67
Principal components regression (PCR) I 40, 52
Prostaglandin I 132, 149
Protease enzymes II 2

- Protease inhibitors, non-peptidic (NPPI)
I 194
- Protein-based drug design, NNRTIs II 77
- Purine bases I 14, 17
- Pyranone analogs I 214
- Pyrazole II 21
- Pyridine-2-carbaldehyde
thiosemicarbazone I 87
- Pyrimidine bases I 14, 17
- Pyriminoizodiamines II 85
- isomers II 97
- QM/MM, hybrid II 70
- QSPR-QSAR theory I 1
- QSSAR I 72
- Quantitative structure-activity relationship
II 249
- Quantum chemical calculations II 56
- Quinolines I 114
- Rational enzyme redesign II 108
- β 3-Receptor agonists II 201
- Retinoic acid receptor I 161
- Reverse transcriptase (RT) I 183; II 58
- Ridge regression (RR) I 40, 52
- Ritonavir I 195
- RNA-dependent DNA polymerase II 58
- RNaseH II 58
- Rosiglitazone I 71, 149, 151
- Self-organizing maps II 93
- Serine proteases II 1, 7
- Sildenafil citrate I 82, 136
- Singlet excitation energy, DNA-RNA bases
I 18
- SMILES I 31
- Sodium nitroprusside I 136
- Steered molecular dynamics (SMD) II 74
- Sterimol I 65; II 22
- Steroid receptor co-activating factor-1
I 163
- Structure-activity relationships (SARs)
I 190; II 252
- Sulfaguanidine II 43
- Tailored molecular similarity I 40
- Tailored similarity I 66
- Tetarazoles I 149
- Tetrahydroisoquinoline II 24
- Tetrahydroquinoline I 115
- Tetrazoles I 159; II 1, 31
- Thalidomide I 84
- Thiazolidin-4-ones II 172
- Thiazolidine II 169
- 1,3-Thiazolidine-2,4-diones I 71
- Thiazolidine-4-carboxylic acids II 170
- Thiazolidinediones I 149, 151, 159,
172
- Thiazolidines II 161
- Thrombin II 1, 5
- Thrombotic disorders II 1
- Thromboxane A2 receptor antagonists
II 211
- TIBO I 27
- TIPAC derivatives II 25
- Tipranavir I 195
- Toxicity I 43
- Transition state isostere I 227
- Transition-state simulation II 108
- Trehalase inhibitors II 240
- Triazoles I 115
- Tripeptidyl thrombin inhibitors
II 37
- Troglitazone (Rezulin) I 71
- Trypsin II 5
- Tryptophan I 8
- Tubocurarine I 84
- Urea derivatives, cyclic I 195
- Valdecoxib I 82, 131
- Verapamil II 249
- Vertex connectivity index I 6
- Virantmycin I 114
- Virtual screening I 149
- Weak interaction I 81
- Zymogen II 5